March 8, 2026 •
The 'Breakthrough' Narrative: Simufilam's Phase 2b Data and Market Reaction The story of Cassava Sciences and its Alzheimer’s drug, simufilam, begins not with a discovery,…
February 13, 2026 • Ekalavya Hansaj
The Zyprexa Papers: A $1.4 Billion Off-Label Marketing Settlement The following investigative review examines the 2009 Zyprexa settlement involving Eli Lilly and Company. The Settlement…
February 13, 2026 • Ekalavya Hansaj
The Irish Subsidiary Scheme: Tracing the $1.4 Billion Tax Shelter Investigation Fiscal year 2012 marked a statistical anomaly for Bristol Myers Squibb. Financial ledgers displayed…
February 13, 2026 • Ekalavya Hansaj
The Humira Patent Thicket: Engineering Extended Exclusivity AbbVie Inc. did not just sell a drug. It constructed a legal fortress around one. Humira (adalimumab) stands…
Enter the 14-digit code sent to your email.